<DOC>
	<DOCNO>NCT00229424</DOCNO>
	<brief_summary>The purpose study verify superiority lafutidine group placebo group non-inferiority famotidine group term endoscopic heal rate patient mild reflux oesophagitis . Furthermore , following compare : The improvement effect heartburn subjective symptom , dose frequency MALFA ® suspension ( neutralizer ) well incidence adverse event among lafutidine 20 mg/day treatment group , famotidine 40 mg/day treatment group placebo treatment group patient mild reflux oesophagitis .</brief_summary>
	<brief_title>Verification Study Lafutidine Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -</brief_title>
	<detailed_description>In Japan report many patient reflux oesophagitis relatively mild usually require strong treatment , even H2 receptor antagonist consider demonstrate sufficient healing effect . Haruma think first choice PPI principle best therapeutic effect medical guideline patient strong reflux symptom heartburn diagnose severe reflux oesophagitis ( Grade C D accord Los Angels Classification ) result upper gastrointestinal endoscopic test . Later , heal confirm 8 week treatment subjective symptom improve , dose PPI reduce half transfer maintenance therapy . On hand , patient mild subjective symptom develop mild reflux oesophagitis ( Grade A B accord Los Angels Classification ) result upper gastrointestinal endoscopic test , 10 % patient aggravate long-run patient heal natural course . Therefore , consider Japanese gastric-acid secretion low Westerners , recommend antacid H2 receptor antagonists sodium alginates use treat symptom appear along improvement lifestyle . As mentioned , lafutidine strongly suppress acid secretion daytime initial phase treatment expect demonstrate sufficient effect treatment mild reflux oesophagitis similar conventional H2 receptor antagonist . Based , clinical trial plan objective confirmedly demonstrate efficacy lafutidine mild reflux oesophagitis . Comparisons : The endoscopic heal rate lafutidine patient mild reflux oesophagitis compare rate placebo also compare rate famotidine .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Lafutidine</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>Age 20 ( time consent give ) Gender inpatient outpatient : Irrelevant Patients diagnose Grade A Grade B mild reflux oesophagitis ( accord Los Angels classification ) endoscopic test Patients complain `` heartburn symptom '' within one week prior enrollment Patients whose `` heartburn symptom '' disappear ( observe ) observation period ( Check official enrollment ) Patients ill compliance dose investigational product observation period ( Not 75 % , check patient dairy official enrollment ) Patients investigator/subinvestigator assess difficult complete patient diary treatment period patient diary observation period many deficiency . ( Check official enrollment ) Patients complication gastric/duodenal ulcer ( scar acceptable ) Patients complication Barrett lining site exceed 3 cm esophageal distal portion Patients receive normal dose H2 receptor antagonist proton pump inhibitor ( PPI ) 8 week vain Patients whose Helicobacter pylori successfully eradicate within 24 week Patients medical history upper gastrointestinal tract excision Patients complication angina pectoris Patients receive treatment investigational product within 12 week Patients show follow value laboratory test official enrollment : Hemoglobin : &lt; 9.5 g/dL , WBC : &lt; 3,000/mm^3 , Thrombocytes : &lt; 75,000/mm^3 , AST ALT : ≥ 100 IU/L , Creatinine : ≥ 1.5 mg/dL These assess use current test value blood drawn within 4 week prior official enrollment . Patients complication serious cardiac disorder ( Grade 3 PAB/SD Notification No . 80 ) For example , patient triplet ventricular premature contraction ( multisources ) use pacemaker Patients medical history serious hypersensitivity drug ( Grade 3 PAB/SD Notification No . 80 ) Patients receive treatment cancer Women confirm potential pregnancy , wish become pregnant , breast feeding woman Patients condition , opinion investigator/subinvestigator disqualifies trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>lafutidine</keyword>
	<keyword>reflux oesophagitis</keyword>
	<keyword>Gastroesophageal Reflux</keyword>
	<keyword>famotidine</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Controlled Study</keyword>
	<keyword>H2 receptor antagonist</keyword>
	<keyword>H2-blocker</keyword>
</DOC>